CMTM5 and myeloid sarcoma: In the present project, we were able to demonstrate that (i) CMTM5 expression is reduced in toxin-induced and inflammatory demyelination animal models; (ii) based on our in vitro experiments, knockdown of Cmtm5 does not seem to affect cell responsiveness to ER stress, which is an early event during oligodendrocyte cytodegeneration; and (iii) that CMTM5 protein expression is reduced in post-mortem MS lesions.